Nwam LLC Buys 193 Shares of Zoetis Inc. (NYSE:ZTS)

Nwam LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,908 shares of the company’s stock after buying an additional 193 shares during the quarter. Nwam LLC’s holdings in Zoetis were worth $959,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mizuho Securities USA LLC raised its holdings in shares of Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after purchasing an additional 4,829,815 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Zoetis by 4.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after buying an additional 178,303 shares during the last quarter. Clearbridge Investments LLC lifted its position in shares of Zoetis by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after buying an additional 166,517 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Zoetis by 17.3% in the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after buying an additional 351,372 shares during the last quarter. Finally, Sarasin & Partners LLP grew its holdings in shares of Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after acquiring an additional 1,904,899 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE ZTS opened at $176.96 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a market cap of $79.84 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. The stock has a fifty day moving average of $185.62 and a 200-day moving average of $180.61.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.36 earnings per share. Equities research analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is currently 32.52%.

Analyst Ratings Changes

ZTS has been the topic of several research analyst reports. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. lifted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.